|
시장보고서
상품코드
1877403
세계의 주사용 세포독성 약물 시장 : 약제 공급원별, 적응증별, 최종 사용자별, 투여 경로별, 약제 클래스별, 국가별, 지역별 - 산업 분석, 규모, 점유율 및 예측(2025-2032년)Injectable Cytotoxic Drugs Market, By Drug Origin, By Indication, By End User, By Route of Administration, By Drug Class, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032 |
||||||
주사용 세포독성 약물 시장 규모는 2024년 196억 2,500만 달러로 평가되었으며, 2025년부터 2032년까지 연평균 복합 성장률(CAGR) 6.50%를 나타낼 전망입니다.
주사용 세포독성 약물 시장이란 암 치료에 사용되는 약제, 특히 주사에 의해 투여되는 약제를 제조, 유통, 판매하는 제약 업계를 말합니다. 세포독성 약물은 세포 분열을 억제하여 암세포를 사멸시키는 데 사용됩니다.
주사용 세포독성 약물 시장 역학
류마티스 관절염 환자 증가는 시장 성장을 가속
류마티스 관절염의 발병률 증가는 주사용 세포독성 약물 시장 전망 성장을 이끌 것으로 예측됩니다. 류마티스 관절염은 지속적인 관절의 염증, 통증, 궁극적으로 관절 손상을 특징으로하는 만성 자가 면역 질환입니다. 인구가 고령화됨에 따라 이 질환의 원인이 되는 유전자 돌연변이와 면역계의 기능부전의 위험이 높아지기 때문에 관절 류마티스가 보다 일반적으로 되고 있습니다. 주사용 세포독성제는 급속하게 분열하는 세포를 표적으로 하고, 과도한 면역반응을 억제함으로써 관절 류마티스의 치료에 도움이 되어, 질병의 진행을 늦추고, 증상을 완화합니다. 예를 들어, 호주에 소재한 독립 법정 기관인 호주 보건복지연구소에 따르면, 류마티스 관절염은 2024년 6월 기준 1,322명의 사망 원인이었으며, 이는 인구 10만 명당 5.1명의 사망률에 해당하고, 2022년 전체 사망자의 0.7%를 차지했습니다. 2023년에는 전체 질병 부담의 2.0%, 근골격계 질환 전체의 부담의 16%를 차지했습니다. 그 결과, 류마티스 관절염 환자 증가는 주사용 세포독성 약물 산업의 성장을 가속하고 있습니다.
주사용 세포독성 약물 시장 : 세분화 분석
세계의 주사용 세포독성 약물 시장은 약물 공급원, 적응증, 최종 사용자, 투여 경로, 약물 클래스, 지역에 따라 구분됩니다.
마약 공급원에 근거한 시장 내역은 다음 세 가지 범주입니다. 일반 항암제, 브랜드 항암제, 제형 항암제 제제(틈새 시장). 주사용 세포독성 약물 시장에서 제네릭 항암제는 현저한 성장이 예상됩니다. 세계적인 암 부담이 꾸준히 증가하는 가운데, 의료 시스템의 대부분이, 저렴한 가격과 입수 가능성의 향상을 목적으로 제네릭 의약품의 활용을 검토하고 있습니다. 일반 주사용 세포독성 약물은 브랜드 제품과 동등한 치료 효과를 저비용으로 제공하므로, 공공 의료 제공업체와 환자 모두에게 합리적인 선택이 됩니다. 정부와 보험사도 특히 장기 암 환자의 의료 비용 절감을 목적으로 제네릭 의약품의 사용을 촉구하기 위한 타겟 광고를 활용하고 있습니다.
시장은 최종 사용자에 따라 병원, 외래수술센터(ASC), 암·전문 클리닉, 재택치료(이동식 점적 유닛 포함), 정부 암 센터 등 5가지 범주로 분류됩니다. 병원 부문은 주사용 세포독성 약물 시장을 주도하고 있습니다. 병원 내의 종양과 또는 암 센터는 주사용 화학요법제와 같은 고급 치료를 제공합니다. 이 시설은 입원 환경에서 모니터링 및 응급 대응 시스템을 강조하는 고위험 세포독성 약물 투여 프로토콜을 준수합니다. 병원에서는 종양내과의사, 방사선과의사, 병리의사가 연계하는 다직종 치료 접근법을 추진하고 있으며, 주사용 세포독성 약물의 투여의 중요성을 강조하고 있습니다. 부작용과 합병증을 원내에서 관리할 수 있기 때문에 세포독성 치료에는 병원이 최적의 선택이 되고 있습니다.
주사용 세포독성 약물 시장 - 지역별 분석
북미는 세계 주사용 세포독성 약물 시장을 주도하고 있습니다. 이 지역에서는 성숙한 종양학 생태계가 구축되어 있어 선진적인 치료 카테고리와 면역요법·방사선요법 등의 신흥 솔루션이 널리 보급되어 있어 고도의 세포독성 치료 영역이 널리 채용되고 있습니다. 또한 암 검진과 조기 진단의 보급도 질병의 조기 단계에서 세포독성 약물를 투여받는 환자의 주사에 대한 접근성 향상에 기여하여 치료 성과 개선과 수요 증가로 이어지고 있습니다.
아시아태평양은 암 증례 증가, 의료 인프라 진전 및 정부 종양학 지원 정책에 견인되어 예측 기간 동안 가장 높은 CAGR로 성장할 것으로 예측됩니다. 정부의 의료 프로그램을 통한 약물의 가용성 향상, 제약 기업과의 제휴 및 종양학 의약품의 현지 생산이 지역 시장의 확대를 추진하고 있습니다. 의료비 지출 증가와 건강 보험의 보급률 상승에 의해 환자님의 질 높은 의료에의 액세스가 개선되고 있습니다.
주사용 세포독성 약물 시장 : 경쟁 구도
주사용 세포독성 약물 시장에서는 종양학 및 화학요법에 특화된 주요 제약 기업이 치열한 경쟁을 펼치고 있습니다. 로슈 홀딩 AG, 사노피 SA, 브리스톨 마이어스 스퀴브, 프레제니우스 곰팡이, 마일란 NV(비아트리스) 등이 시장을 선도하는 기업군입니다. 이러한 기업들은 약물 개발, 국제 공급망, 전략적 제휴를 통한 종양학 포트폴리오의 확충에 선구적인 역할을 하고 있습니다. 게다가 세계적으로 특히 북미와 아시아태평양 등 주요 시장에서의 암 발생률의 상승과 주사 요법에 대한 접근 확대가 함께 경쟁을 촉진하고 있습니다. 각 회사는 규제 당국의 승인 취득, 제네릭 의약품의 발매, 특히 병원 약국 채널에서의 제조 규모의 확대 등의 능력에 의해 차별화를 도모하고 있습니다.
목차
제1장 주사용 세포독성 약물 시장 개요
- 분석 범위
- 시장 추정 기간
제2장 주요 요약
- 시장 분석
- 경쟁 인사이트
제3장 주사용 세포독성 약물의 주요 시장 동향
- 시장 성장 촉진요인
- 시장 성장 억제요인
- 시장 기회
- 시장 전망 동향
제4장 주사용 세포독성 약물 시장 : 산업 분석
- PEST 분석
- Porter's Five Forces 분석
- 시장 성장 전망 : 매핑
- 규제 체제의 분석
제5장 주사용 세포독성 약물 시장 : 높아지는 지정학적 긴장의 영향
- COVID-19 팬데믹의 영향
- 러시아·우크라이나 전쟁의 영향
- 중동 분쟁의 영향
제6장 주사용 세포독성 약물 시장 상황
- 주사용 세포독성 약물 시장 점유율 분석(2024년)
- 주요 제조업체별 분석 데이터
- 기존 기업의 분석
- 신흥 기업의 분석
제7장 주사용 세포독성 약물 시장 : 약제 공급원별
- 개요
- 부문별 점유율 분석 : 약제 공급원별
- 복합 세포독성 약물(니치)
- 일반 세포독성 약물
- 브랜드 세포독성 약물
제8장 주사용 세포독성 약물 시장 : 적응증별
- 개요
- 부문별 점유율 분석 : 적응증별
- 방광암 및 전립선암
- 유방암
- 혈액 악성 종양
- 난소 및 자궁경부암
- 췌장 및 간암
- 폐암
- 대장암
- 기타(육종, 두경부암, 위암)
제9장 주사용 세포독성 약물 시장 : 최종 사용자별
- 개요
- 부문별 점유율 분석 : 최종 사용자별
- 외래수술센터(ASC)
- 암 및 전문 클리닉
- 병원
- 재택치료(이동식 주입 장치 포함)
- 정부 암 센터
제10장 주사용 세포독성 약물 시장 : 투여 경로별
- 개요
- 부문별 점유율 분석 : 투여 경로별
- 근육 내(IM)
- 복강 내(HIPEC 프로토콜에 사용됨)
- 척수강 내
- 정맥주사(IV) 주입
- 피하(일부 약제용)
- 복강 내(HIPEC 프로토콜에 사용됨)
제11장 주사용 세포독성 약물 시장 : 약제 클래스별
- 개요
- 부문별 점유율 분석 : 약물 클래스별
- 식물 알칼로이드
- 세포독성 항체
- 항대사제
- 알킬화제
- 기타
제12장 주사용 세포독성 약물 시장 : 지역별
- 서론
- 북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
- 유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
- 아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
- 라틴아메리카(LATAM)
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
- 중동 및 아프리카(MEA)
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 튀르키예
- 알제리
- 이집트
- 기타
제13장 주요 벤더 분석 : 주사용 세포독성 약물 업계
- 경쟁 대시보드
- 경쟁 벤치마킹
- 경쟁 포지셔닝
- 기업 프로파일
- Johnson and Johnson Services Inc.
- Roche Holding AG
- Sanofi SA
- Merck &Co. Inc.
- Bristol-Myers Squibb
- Intas Pharmaceuticals Ltd.
- Natco Pharma
- Zydus Lifesciences Ltd.
- Fresenius Kabi
- Mylan NV(Viatris)
- Hikma Pharmaceuticals PLC
- Pfizer Inc.
- Novartis AG(Sandoz-generics)
- Eli Lilly and Company
- Dr. Reddy's Laboratories
- Sun Pharmaceutical Industries Ltd.
- Cipla Ltd.
- Aurobindo Pharma
- Accord Healthcare
- Hospira(a Pfizer company)
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals
- Others
제14장 AnalystView의 전방위 분석
KTH 25.12.15Injectable Cytotoxic Drugs Market size was valued at US$ 19,625 Million in 2024, expanding at a CAGR of 6.50% from 2025 to 2032.
The injectable cytotoxic drugs market is the pharmaceutical industry that produces, distributes, and sells drugs used to treat cancer, specifically those administered via injection. Cytotoxic drugs are used to kill cancer cells by inhibiting cell division, causing the cells to die.
Injectable Cytotoxic Drugs Market- Market Dynamics
Rising Prevalence of Rheumatoid Arthritis Propels Market Growth
The rising incidence of rheumatoid arthritis is expected to drive future growth in the injectable cytotoxic drugs market. Rheumatoid arthritis is a chronic autoimmune disorder characterized by ongoing joint inflammation, pain, and eventual joint damage. Rheumatoid arthritis is becoming more common as the population ages, increasing the risk of genetic mutations and immune system dysfunction that contribute to the condition. Injectable cytotoxic drugs help treat rheumatoid arthritis by targeting rapidly dividing cells and suppressing overactive immune responses, which slows disease progression and alleviates symptoms. For instance, according to the Australian Institute of Health and Welfare, an independent statutory agency based in Australia, rheumatoid arthritis was responsible for 1,322 deaths in June 2024, equating to 5.1 deaths per 100,000 people, and 0.7% of all deaths in 2022. It accounted for 2.0% of the overall disease burden and 16% of the total burden from all musculoskeletal conditions in 2023. As a result, the rising prevalence of rheumatoid arthritis is fueling the growth of the injectable cytotoxic drug industry.
Injectable Cytotoxic Drugs Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.50% over the forecast period (2025-2032)
Based on Drug Origin segmentation, Generic cytotoxic drugs are expected to grow rapidly in the injectable cytotoxic drug market.
Based on Indication segmentation, the hematological malignancies segment is expected to grow at the fastest rate in the injectable cytotoxic drugs market.
Based on End User segmentation, Hospitals is the leading End User in 2025
Based on Route of Administration segmentation, intravenous injection/infusion is the leading Route of Administration in 2025
Based on Drug Class segmentation, alkylating is predicted to show maximum market share in the year 2025
On the basis of region, North America is the leading revenue generator in 2025
Injectable Cytotoxic Drugs Market- Segmentation Analysis:
The Global Injectable Cytotoxic Drugs Market is segmented by Drug Origin, Indication, End User, Route of Administration, Drug Class, and Region.
The market is divided into three categories based on Drug Origin: Generic Cytotoxic Drugs, Branded Cytotoxic Drugs, and Compounded Cytotoxic Preparations (niche). Generic cytotoxic drugs are expected to experience significant growth in the injectable cytotoxic drugs market. With the global cancer burden steadily increasing, a growing number of healthcare systems are looking into using generics to improve affordability and accessibility. Generic injectable cytotoxic drugs provide the same therapeutic benefits as their brand counterparts at a lower cost, making them an affordable option for both public healthcare providers and patients. Governments and insurance companies also use targeted advertising to encourage people to use generic drugs in order to reduce healthcare costs, particularly for long-term cancer patients.
The market is divided into five categories based on End User: Hospitals, Ambulatory Surgical Centers (ASCs), Cancer & Specialty Clinics, Homecare Settings (with mobile infusion units), and Government Oncology Centers. The hospital segment dominates the injectable cytotoxic drugs market. Oncology departments or cancer centers in hospitals have advanced treatments such as injectable chemotherapy. These facilities follow high-risk cytotoxic drug administration protocols, emphasizing monitoring and emergency support systems found in inpatient settings. Hospitals encourage multidisciplinary treatment approaches in which medical oncologists, radiologists, and pathologists collaborate, emphasising the importance of administering injectable cytotoxic drugs. Hospitals are the preferred choice for cytotoxic treatments because they can manage side effects and complications on-site.
Injectable Cytotoxic Drugs Market- Geographical Insights
North America dominates the global injectable cytotoxic drugs market. The advanced cytotoxic treatment area is widely adopted because the region's mature oncology ecosystem allows for widespread adoption of advanced treatment categories, as well as emerging solutions such as immunotherapy and radiation, among others. The prevalence of cancer screening and early diagnosis also contributes to increased access to injections for patients who receive cytotoxic drugs earlier in the course of the disease, improving treatment outcomes and increasing demand.
The Asia Pacific is expected to grow at the fastest CAGR during the forecast period, driven by rising cancer cases, advancements in healthcare infrastructure, and supportive government oncology policies. The regional market's expansion is being driven by increased drug availability through government healthcare programs, collaborations with pharmaceutical companies, and local production of oncology medicines. Increased healthcare spending and rising health insurance penetration improve patient access to quality medical care.
Injectable Cytotoxic Drugs Market- Competitive Landscape:
In the injectable cytotoxic drugs market, major pharmaceutical companies focused on oncology and chemotherapy compete fiercely. Roche Holding AG, Sanofi S.A., Bristol-Myers Squibb, Fresenius Kabi, and Mylan N.V. (Viatris) are among the market leaders. These companies are pioneers in drug development, global supply, and strategic alliances to broaden their oncology portfolios. Moreover, the combination of rising cancer incidence worldwide, particularly in key markets such as North America and Asia-Pacific, and increased access to injectable therapies is driving competition. Players are distinguished by their ability to obtain regulatory approvals, launch generic products, and scale manufacturing, particularly in hospital pharmacy channels.
Recent Developments:
In February 2024, Novartis agreed to pay 2.7 billion Euros in a voluntary public takeover offer to acquire MorphoSys AG, a global, German-based biopharmaceutical company that produces oncology drugs.
In May 2023, Innovent Biologics and Inc. and Eli Lilly and Company jointly announced the National Medical Products Administration of China has approved the supplemental New Drug Application (sNDA) for TYVYT (sintilimab injection) when used alongside bevacizumab and chemotherapy (pemetrexed and cisplatin) for individuals with non-squamous non-small cell lung cancer.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Johnson and Johnson Services Inc.
- Roche Holding AG
- Sanofi S.A.
- Merck & Co. Inc.
- Bristol-Myers Squibb
- Intas Pharmaceuticals Ltd.
- Natco Pharma
- Zydus Lifesciences Ltd.
- Fresenius Kabi
- Mylan N.V. (Viatris)
- Hikma Pharmaceuticals PLC
- Pfizer Inc.
- Novartis AG (Sandoz - generics)
- Eli Lilly and Company
- Dr. Reddy's Laboratories
- Sun Pharmaceutical Industries Ltd.
- Cipla Ltd.
- Aurobindo Pharma
- Accord Healthcare
- Hospira (a Pfizer company)
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals
- Others
GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY DRUG ORIGIN- MARKET ANALYSIS, 2019 - 2032
- Compounded Cytotoxic Preparations (niche)
- Generic Cytotoxic Drugs
- Branded Cytotoxic Drugs
GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032
- Bladder & Prostate Cancer
- Breast Cancer
- Hematological Malignancies
- Ovarian & Cervical Cancer
- Pancreatic & Liver Cancer
- Lung Cancer
- Colorectal Cancer
- Others (Sarcoma, Head & Neck, Gastric)
GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
- Ambulatory Surgical Centers (ASCs)
- Cancer & Specialty Clinics
- Hospitals
- Homecare Settings (with mobile infusion units)
- Government Oncology Centers
GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
- Intramuscular (IM)
- Intraperitoneal (used in HIPEC protocols)
- Intrathecal
- Intravenous (IV) Injection/Infusion
- Subcutaneous (for select agents)
- Intraperitoneal (used in HIPEC protocols)
GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032
- Plant Alkaloids
- Cytotoxic Antibodies
- Antimetabolites
- Alkylating Drugs
- Others
GLOBAL INJECTABLE CYTOTOXIC DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Table of Contents
1. Injectable Cytotoxic Drugs Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.1.1. Injectable Cytotoxic Drugs Market Snippet by Drug Origin
- 2.1.2. Injectable Cytotoxic Drugs Market Snippet by Indication
- 2.1.3. Injectable Cytotoxic Drugs Market Snippet by End User
- 2.1.4. Injectable Cytotoxic Drugs Market Snippet by Route of Administration
- 2.1.5. Injectable Cytotoxic Drugs Market Snippet by Drug Class
- 2.1.6. Injectable Cytotoxic Drugs Market Snippet by Country
- 2.1.7. Injectable Cytotoxic Drugs Market Snippet by Region
- 2.2. Competitive Insights
3. Injectable Cytotoxic Drugs Key Market Trends
- 3.1. Injectable Cytotoxic Drugs Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Injectable Cytotoxic Drugs Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Injectable Cytotoxic Drugs Market Opportunities
- 3.4. Injectable Cytotoxic Drugs Market Future Trends
4. Injectable Cytotoxic Drugs Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Injectable Cytotoxic Drugs Market: Impact of Escalating Geopolitical Tensions
- 5.1. Impact of COVID-19 Pandemic
- 5.2. Impact of Russia-Ukraine War
- 5.3. Impact of Middle East Conflicts
6. Injectable Cytotoxic Drugs Market Landscape
- 6.1. Injectable Cytotoxic Drugs Market Share Analysis, 2024
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Injectable Cytotoxic Drugs Market - By Drug Origin
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Origin, 2024 & 2032 (%)
- 7.1.1.1. Compounded Cytotoxic Preparations (niche)
- 7.1.1.2. Generic Cytotoxic Drugs
- 7.1.1.3. Branded Cytotoxic Drugs
- 7.1.1. Segment Share Analysis, By Drug Origin, 2024 & 2032 (%)
8. Injectable Cytotoxic Drugs Market - By Indication
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
- 8.1.2. Bladder & Prostate Cancer
- 8.1.3. Breast Cancer
- 8.1.4. Hematological Malignancies
- 8.1.5. Ovarian & Cervical Cancer
- 8.1.6. Pancreatic & Liver Cancer
- 8.1.7. Lung Cancer
- 8.1.8. Colorectal Cancer
- 8.1.9. Others (Sarcoma, Head & Neck, Gastric)
9. Injectable Cytotoxic Drugs Market - By End User
- 9.1. Overview
- 9.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
- 9.1.2. Ambulatory Surgical Centers (ASCs)
- 9.1.3. Cancer & Specialty Clinics
- 9.1.4. Hospitals
- 9.1.5. Homecare Settings (with mobile infusion units)
- 9.1.6. Government Oncology Centers
10. Injectable Cytotoxic Drugs Market - By Route of Administration
- 10.1. Overview
- 10.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
- 10.1.2. Intramuscular (IM)
- 10.1.3. Intraperitoneal (used in HIPEC protocols)
- 10.1.4. Intrathecal
- 10.1.5. Intravenous (IV) Injection/Infusion
- 10.1.6. Subcutaneous (for select agents)
- 10.1.7. Intraperitoneal (used in HIPEC protocols)
11. Injectable Cytotoxic Drugs Market - By Drug Class
- 11.1. Overview
- 11.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
- 11.1.2. Plant Alkaloids
- 11.1.3. Cytotoxic Antibodies
- 11.1.4. Antimetabolites
- 11.1.5. Alkylating Drugs
- 11.1.6. Others
12. Injectable Cytotoxic Drugs Market- By Geography
- 12.1. Introduction
- 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
- 12.2. North America
- 12.2.1. Overview
- 12.2.2. Injectable Cytotoxic Drugs Key Manufacturers in North America
- 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.2.4. North America Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.2.7. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.2.8. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.2.9. U.S.
- 12.2.9.1. Overview
- 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.2.9.3. U.S. Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.2.9.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.2.9.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.2.9.6. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.2.9.7. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.2.10. Canada
- 12.2.10.1. Overview
- 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.2.10.3. Canada Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.2.10.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.2.10.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.2.10.6. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.2.10.7. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.3. Europe
- 12.3.1. Overview
- 12.3.2. Injectable Cytotoxic Drugs Key Manufacturers in Europe
- 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.3.4. Europe Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.7. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.8. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.3.9. Germany
- 12.3.9.1. Overview
- 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.9.3. Germany Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.3.9.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.3.9.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.9.6. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.9.7. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.3.10. UK
- 12.3.10.1. Overview
- 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.10.3. UK Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.3.10.4. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.3.10.5. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.10.6. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.10.7. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.3.11. France
- 12.3.11.1. Overview
- 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.11.3. France Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.3.11.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.3.11.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.11.6. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.11.7. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.3.12. Italy
- 12.3.12.1. Overview
- 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.12.3. Italy Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.3.12.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.3.12.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.12.6. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.12.7. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.3.13. Spain
- 12.3.13.1. Overview
- 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.13.3. Spain Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.3.13.4. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.3.13.5. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.13.6. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.13.7. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.3.14. The Netherlands
- 12.3.14.1. Overview
- 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.14.3. The Netherlands Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.3.14.4. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.3.14.5. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.14.6. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.14.7. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.3.15. Sweden
- 12.3.15.1. Overview
- 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.15.3. Sweden Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.3.15.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.3.15.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.15.6. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.15.7. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.3.16. Russia
- 12.3.16.1. Overview
- 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.16.3. Russia Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.3.16.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.3.16.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.16.6. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.16.7. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.3.17. Poland
- 12.3.17.1. Overview
- 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.17.3. Poland Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.3.17.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.3.17.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.17.6. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.17.7. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.3.18. Rest of Europe
- 12.3.18.1. Overview
- 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.18.3. Rest of the Europe Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.3.18.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.3.18.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.18.6. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.18.7. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.4. Asia Pacific (APAC)
- 12.4.1. Overview
- 12.4.2. Injectable Cytotoxic Drugs Key Manufacturers in Asia Pacific
- 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.4.4. APAC Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.4.5. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.4.6. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.7. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.8. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.4.9. China
- 12.4.9.1. Overview
- 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.9.3. China Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.4.9.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.4.9.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.9.6. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.9.7. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.4.10. India
- 12.4.10.1. Overview
- 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.10.3. India Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.4.10.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.4.10.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.10.6. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.10.7. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.4.11. Japan
- 12.4.11.1. Overview
- 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.11.3. Japan Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.4.11.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.4.11.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.11.6. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.11.7. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.4.12. South Korea
- 12.4.12.1. Overview
- 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.12.3. South Korea Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.4.12.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.4.12.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.12.6. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.12.7. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.4.13. Australia
- 12.4.13.1. Overview
- 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.13.3. Australia Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.4.13.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.4.13.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.13.6. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.13.7. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.4.14. Indonesia
- 12.4.14.1. Overview
- 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.14.3. Indonesia Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.4.14.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.4.14.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.14.6. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.14.7. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.4.15. Thailand
- 12.4.15.1. Overview
- 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.15.3. Thailand Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.4.15.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.4.15.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.15.6. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.15.7. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.4.16. Philippines
- 12.4.16.1. Overview
- 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.16.3. Philippines Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.4.16.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.4.16.5. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.16.6. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.16.7. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.4.17. Rest of APAC
- 12.4.17.1. Overview
- 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.17.3. Rest of APAC Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.4.17.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.4.17.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.17.6. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.17.7. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.5. Latin America (LATAM)
- 12.5.1. Overview
- 12.5.2. Injectable Cytotoxic Drugs Key Manufacturers in Latin America
- 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.5.4. LATAM Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.5.5. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.5.6. LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.7. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.8. LATAM Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.5.9. Brazil
- 12.5.9.1. Overview
- 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.5.9.3. Brazil Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.5.9.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.5.9.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.9.6. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.9.7. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.5.10. Mexico
- 12.5.10.1. Overview
- 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.5.10.3. Mexico Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.5.10.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.5.10.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.10.6. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.10.7. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.5.11. Argentina
- 12.5.11.1. Overview
- 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.5.11.3. Argentina Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.5.11.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.5.11.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.11.6. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.11.7. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.5.12. Colombia
- 12.5.12.1. Overview
- 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.5.12.3. Colombia Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.5.12.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.5.12.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.12.6. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.12.7. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.5.13. Rest of LATAM
- 12.5.13.1. Overview
- 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.5.13.3. Rest of LATAM Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.5.13.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.5.13.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.13.6. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.13.7. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.6. Middle East and Africa
- 12.6.1. Overview
- 12.6.2. Injectable Cytotoxic Drugs Key Manufacturers in Middle East and Africa
- 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.6.4. Middle East and Africa Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.6.6. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.7. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.8. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.6.9. Saudi Arabia
- 12.6.9.1. Overview
- 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.9.3. Saudi Arabia Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.6.9.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.6.9.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.9.6. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.9.7. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.6.10. United Arab Emirates
- 12.6.10.1. Overview
- 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.10.3. United Arab Emirates Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.6.10.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.6.10.5. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.10.6. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.10.7. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.6.11. Israel
- 12.6.11.1. Overview
- 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.11.3. Israel Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.6.11.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.6.11.5. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.11.6. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.11.7. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.6.12. Turkey
- 12.6.12.1. Overview
- 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.12.3. Turkey Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.6.12.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.6.12.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.12.6. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.12.7. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.6.13. Algeria
- 12.6.13.1. Overview
- 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.13.3. Algeria Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.6.13.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.6.13.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.13.6. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.13.7. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.6.14. Egypt
- 12.6.14.1. Overview
- 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.14.3. Egypt Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.6.14.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.6.14.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.14.6. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.14.7. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.6.15. Rest of MEA
- 12.6.15.1. Overview
- 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.15.3. Rest of MEA Market Size and Forecast, By Drug Origin, 2019 - 2032 (US$ Million)
- 12.6.15.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.6.15.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.15.6. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.15.7. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13. Key Vendor Analysis- Injectable Cytotoxic Drugs Industry
- 13.1. Competitive Benchmarking
- 13.1.1. Competitive Dashboard
- 13.1.2. Competitive Positioning
- 13.2. Company Profiles
- 13.2.1. Johnson and Johnson Services Inc.
- 13.2.2. Roche Holding AG
- 13.2.3. Sanofi S.A.
- 13.2.4. Merck & Co. Inc.
- 13.2.5. Bristol-Myers Squibb
- 13.2.6. Intas Pharmaceuticals Ltd.
- 13.2.7. Natco Pharma
- 13.2.8. Zydus Lifesciences Ltd.
- 13.2.9. Fresenius Kabi
- 13.2.10. Mylan N.V. (Viatris)
- 13.2.11. Hikma Pharmaceuticals PLC
- 13.2.12. Pfizer Inc.
- 13.2.13. Novartis AG (Sandoz - generics)
- 13.2.14. Eli Lilly and Company
- 13.2.15. Dr. Reddy's Laboratories
- 13.2.16. Sun Pharmaceutical Industries Ltd.
- 13.2.17. Cipla Ltd.
- 13.2.18. Aurobindo Pharma
- 13.2.19. Accord Healthcare
- 13.2.20. Hospira (a Pfizer company)
- 13.2.21. Teva Pharmaceutical Industries Ltd.
- 13.2.22. Amneal Pharmaceuticals
- 13.2.23. Others
14. 360 Degree Analyst View
15. Appendix
- 15.1. Research Methodology
- 15.2. References
- 15.3. Abbreviations
- 15.4. Disclaimer
- 15.5. Contact Us
